Skye Bioscience (Skye Bioscience) Cash-to-Debt : 17.23 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Skye Bioscience's cash to debt ratio for the quarter that ended in Mar. 2024 was 17.23.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Skye Bioscience could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Skye Bioscience's Cash-to-Debt or its related term are showing as below:

SKYE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 3.67 Max: No Debt
Current: 17.23

During the past 12 years, Skye Bioscience's highest Cash to Debt Ratio was No Debt. The lowest was 0.08. And the median was 3.67.

SKYE's Cash-to-Debt is ranked better than
63.13% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs SKYE: 17.23

Skye Bioscience Cash-to-Debt Historical Data

The historical data trend for Skye Bioscience's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Skye Bioscience Cash-to-Debt Chart

Skye Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

4.73

1.65

4.21

0.63

0.27

Skye Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															11.12	1.52	1.16	0.27	17.23

Competitive Comparison of Skye Bioscience's Cash-to-Debt

For the Biotechnology subindustry, Skye Bioscience's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Skye Bioscience's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Cash-to-Debt falls into.

Skye Bioscience Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Skye Bioscience's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.256	/	(4.444	+	0.171)
	=	0.27

Skye Bioscience's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	83.343	/	(4.685	+	0.151)
	=	17.23

Skye Bioscience (NAS:SKYE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Skye Bioscience Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Skye Bioscience (Skye Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130

Website

https://www.skyebioscience.com

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.

Executives

Punit Dhillon	director	5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
John D Diekman	10 percent owner	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vii, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Paul A. Grayson	director	10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
5am Ventures Vii, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Ventures Iii, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Side Fund Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
5am Ventures Ii Lp	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Deborah H. Charych	director	1001 17TH ST, SAN FRANCISCO CA 94107